Group 1 - Aptiv PLC (APTV) has experienced significant selling pressure, resulting in a 20.7% decline over the past four weeks, but it is now considered to be in oversold territory with expectations of better earnings ahead [1] - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - APTV's current RSI reading is 25.58, suggesting that the heavy selling may be exhausting itself, indicating a potential price rebound [5] Group 2 - There is a strong consensus among sell-side analysts to raise earnings estimates for APTV, with a 0.3% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7] - APTV holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8]

Core Viewpoint - Chimera Investment (CIM) has experienced significant selling pressure, declining 7.7% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - CIM's current RSI reading is 28.62, suggesting that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for CIM, with a 0.6% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7]. - CIM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Riot Platforms Inc. RIOT just flashed a major warning signal, officially forming a Death Cross as its 50-day simple moving average sank below the 200-day moving average. While shares jumped 3.93% by early afternoon on Monday, the broader trend remains bearish – down 29.3% year to date and a 35.5% in the past year. Chart created using Benzinga Pro Read Also: Bitcoin Miners Core Scientific, Riot Platforms, CleanSpark, Iris Energy See Price Targets Slashed: Bernstein A Bearish Storm Brewing Technicals paint a ...

Group 1 - Ginkgo Bioworks Holdings, Inc. (DNA) has experienced a significant decline of 28.8% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for DNA is currently at 20.73, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a reversal towards the previous equilibrium of supply and demand [5] - There is strong consensus among Wall Street analysts that DNA will report better earnings than previously predicted, with the consensus EPS estimate increasing by 37.9% over the last 30 days [7] Group 2 - DNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - Inovio Pharmaceuticals (INO) has experienced significant selling pressure, resulting in an 11.4% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - INO's current RSI reading is 25.47, suggesting that the heavy selling may be nearing exhaustion, potentially leading to a price rebound [5] Group 2: Fundamental Analysis - There is a strong consensus among sell-side analysts to raise earnings estimates for INO, with a 33.4% increase in the consensus EPS estimate over the last 30 days [7] - INO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a favorable outlook for a potential turnaround [8]

Core Viewpoint - Kodiak Sciences Inc. (KOD) has experienced significant selling pressure, resulting in a 28.1% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key indicator for identifying oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - KOD's current RSI reading is 27.59, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back [5] Group 2: Fundamental Analysis - There is a strong consensus among sell-side analysts to raise earnings estimates for KOD, with a 3.3% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7] Group 3: Analyst Ratings - KOD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Verizon Communications Inc. VZ is dialing up a bullish breakout as its stock pushes past key technical levels. With shares up 12.76% year to date and 5.20% in the past month, Verizon stock has now confirmed a golden cross, a classic bullish indicator signaling potential for more upside. Chart created using Benzinga Pro Read Also: EXCLUSIVE: Why Defiance ETF CEO Sees Big Gains Ahead During Nvidia's 6G Revolution Verizon Stock Technicals Confirm A Strong Uptrend At $44.93, Verizon stock is currently above its ...

Core Viewpoint - Hyliion Holdings Corp. (HYLN) has experienced significant selling pressure, resulting in a 16.6% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - HYLN's current RSI reading is 29.79, suggesting that the stock may be nearing a reversal point due to the exhaustion of selling pressure [5]. Group 2: Fundamental Indicators - Analysts have raised earnings estimates for HYLN by 6.3% over the last 30 days, indicating a consensus among sell-side analysts that could lead to price appreciation [7]. - HYLN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which further supports the potential for a turnaround [8].

Group 1 - Genelux Corporation (GNLX) has experienced a significant decline of 29.7% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for GNLX is currently at 29.16, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that GNLX will report better earnings than previously predicted, with a 33% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - GNLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - Acrivon Therapeutics, Inc. (ACRV) has experienced a significant decline of 52.8% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - ACRV's current RSI reading is 23.16, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium [5]. Group 2: Fundamental Analysis - There is a consensus among sell-side analysts that earnings estimates for ACRV have increased by 4.3% over the last 30 days, which typically correlates with price appreciation [6]. - ACRV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].